Sakar Healthcare Secures Second EU Nod for Oncology Injection—Boosts Global Oncology Play

Image Source : YouTube

Sakar Healthcare Ltd. has received its second Marketing Authorization (MA) from the European Union for one of its liquid oncology injections, marking another milestone in the company’s global expansion strategy. This approval follows the company’s earlier EU nod and comes on the back of its EU GMP-certified oncology facility in Bavla, Gujarat.

The newly approved product is part of a broader portfolio of 20 oncology dossiers submitted across regulated markets. With this second MA, Sakar is now poised to scale exports to Europe, tapping into high-margin opportunities in the anti-cancer therapeutics segment.

Key Highlights:

Second EU Marketing Authorization granted for oncology injection.
Facility: EU GMP-certified oncology unit in Bavla, Gujarat.
Strategic impact: Strengthens Sakar’s foothold in regulated markets.
Pipeline: 7 more oncology products under EU review.
Export potential: Opens doors to broader European distribution and licensing deals.
Stock impact: Shares gained intraday on news of regulatory progress.

This development reinforces Sakar’s ambition to become a global oncology formulation partner, especially in injectables and lyophilized therapies.

Source: Trade Brains | Sakar Healthcare Announcements